Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Central Nervous System Neoplasms 5Neuroblastoma 3Gliosarcoma 3Glioblastoma 3Testicular Germ Cell Tumor 2Ovarian Neoplasms 2Lymphoma 2Brain Neoplasms 2Wilms Tumor 1Testicular Neoplasms 1Teratoma 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Nephroma, Mesoblastic 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Temozolomide 1Microarray Analysis 1Dexamethasone 1DNA Methylation 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Basophil × Microarray Analysis × CNS × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡